Stock SAGE SAGE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Sage Therapeutics, Inc.

Equities

SAGE

US78667J1088

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
13.69 USD +0.81% Intraday chart for Sage Therapeutics, Inc. +2.70% -36.83%
Apr. 25 Truist Securities Cuts Sage Therapeutics' Price Target to $18 From $22, Hold Rating Maintained MT
Apr. 25 Transcript : Sage Therapeutics, Inc., Q1 2024 Earnings Call, Apr 25, 2024

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sage Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Earnings Focus Lifts Exchange-Traded Funds, Equity Futures Pre-Bell Wednesday
Sage Therapeutics, Inc. Announces Topline Results from Phase 2 PRECEDENT Study of DalzanemDor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson's Disease
Sage Therapeutics, Inc. Announces the Retirement of Steven Paul from the Board
Sector Update: Health Care Stocks Edge Higher Premarket Wednesday
Sage Therapeutics Q4 Net Loss Narrows, Net Product Revenue Declines
Sage Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Sage Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Sage Therapeutics, Inc. Enters into Lease Agreement with 55 Cambridge Parkway, LLC
Sage Therapeutics, Inc. Announces Changes to Board of Directors
Biogen, Sage Therapeutics Say Oral Pill Zurzuvae for Postpartum Depression Now Available by Prescription in US
Sage Therapeutics, Inc. and Biogen Inc. Announces ZURZUVAE 50 mg (Two 25 mg Capsules Per Day) CIV
Sage Therapeutics Q3 Loss Widens; Revenue Rises
Biogen-Sage Therapeutics postpartum depression pill priced at $15,900
Sage Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Sage Therapeutics Says US FDA Grants SAGE-718 Orphan Drug Designation for the Treatment of Huntington's Disease
Sage Therapeutics, Inc. Announces U.S. Food and Drug Administration Granted Sage-718 Orphan Drug Designation for the Treatment of Huntington's Disease
Sage Therapeutics to Lay Off 40% Staff Amid Efforts to Support Financial Position
Sage Therapeutics, Inc. Announces Reduction of the Workforce by Approximately 40%
Sage Therapeutics to cut 40% of jobs after depression drug setback
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SAGE Stock
  4. News Sage Therapeutics, Inc.
  5. Other languages